Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1795111 | 0.87 | ALOX5AP (0.62) | ALOX5APFEN1 | |
| SCHEMBL9122272 | 0.86 | ALOX5AP (0.65) | ALOX5APFEN1 | |
| SCHEMBL6763724 | 0.84 | ALOX5AP (0.62) | ALOX5APFEN1 | |
| SCHEMBL15915740 | 0.84 | ALOX5AP (0.65) | ALOX5APFEN1 | |
| SCHEMBL6769724 | 0.84 | ALOX5AP (0.62) | ALOX5APFEN1 | |
| SCHEMBL15936747 | 0.82 | ALOX5AP (0.62) | ALOX5APFEN1 | |
| SCHEMBL15917570 | 0.82 | ALOX5AP (1.00) | ALOX5APFEN1 | |
| SCHEMBL15916277 | 0.82 | ALOX5AP (0.61) | ALOX5APFEN1 | |
| SCHEMBL15917332 | 0.81 | ALOX5AP (1.00) | ALOX5APFEN1 | |
| SCHEMBL3828691 | 0.81 | ALOX5AP (0.61) | ALOX5APFEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7718659-B2 | Heteroarylacetamide inhibitors of factor Xa | HOFFMANN-LA ROCHE INC. (US) | 2010-05-18 | — | — | US | disclosed |
| US-20090221546-A1 | INHIBITORS OF FACTOR XA AND OTHER SERINE PROTEASES INVOLVED IN THE COAGULATION CASCADE | PFIZER INC | 2009-09-03 | — | — | US | disclosed |
| EP-2085391-A2 | Inhibitors of factor XA and other serine proteases involved in the coagulation cascade | Warner-Lambert Company LLC (US) | 2009-08-05 | — | — | EP | disclosed |
| US-7459468-B2 | Aryl sulfonic pyridoxines as antiplatelet agents | MEDICURE INTERNATIONAL, INC. (BB) | 2008-12-02 | — | — | US | disclosed |
| US-7459468-B2 | Aryl sulfonic pyridoxines as antiplatelet agents | MEDICURE INTERNATIONAL, INC. (BB) | 2008-12-02 | — | — | US | disclosed |
| US-7459468-B2 | Aryl sulfonic pyridoxines as antiplatelet agents | MEDICURE INTERNATIONAL, INC. (BB) | 2008-12-02 | — | — | US | disclosed |
| US-20080287674-A1 | Inhibitors of Factor XA and Other Serine Proteases Involved in the Coagulation Cascade | WARNER-LAMBERT COMPANY LLC | 2008-11-20 | — | — | US | disclosed |
| US-7407974-B2 | Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade | PFIZER INC. (US) | 2008-08-05 | — | — | US | disclosed |
| US-7407972-B2 | Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade | PFIZER INC. (US) | 2008-08-05 | — | — | US | disclosed |
| EP-1671949-B1 | Substituted Pyridinylamines | WARNER LAMBERT CO (US) | 2008-07-23 | — | — | EP | disclosed |
| EP-1159264-A2 | INHIBITORS OF FACTOR Xa | COR THERAPEUTICS, INC. (US) | 2001-12-05 | — | — | EP | disclosed |
| US-6271237-B1 | ANTICOAGULANTS | DUPONT PHARMACEUTICALS COMPANY | 2001-08-07 | — | — | US | disclosed |
| WO-1999032454-A9 | NITROGEN CONTAINING HETEROAROMATICS WITH ORTHO-SUBSTITUTED P1'S AS FACTOR XA INHIBITORS | DU PONT PHARM CO (US) | 2001-05-31 | — | — | WO | disclosed |
| WO-2001019798-A2 | INHIBITORS OF FACTOR Xa | COR THERAPEUTICS INC. (US) | 2001-03-22 | — | — | WO | disclosed |
| WO-2000071510-A2 | INHIBITORS OF FACTOR Xa | COR THERAPEUTICS, INC. (US) | 2000-11-30 | — | — | WO | disclosed |
| WO-2000071507-A2 | INHIBITORS OF FACTOR Xa | COR THERAPEUTICS, INC. (US) | 2000-11-30 | — | — | WO | disclosed |
| WO-2000071512-A1 | INHIBITORS OF FACTOR Xa | COR THERAPEUTICS, INC. (US) | 2000-11-30 | — | — | WO | disclosed |
| EP-1042299-A1 | NITROGEN CONTAINING HETEROAROMATICS WITH ORTHO-SUBSTITUTED P1'S AS FACTOR XA INHIBITORS | Du Pont Pharmaceuticals Company (US) | 2000-10-11 | — | — | EP | disclosed |
| WO-2000047554-A2 | INHIBITORS OF FACTOR Xa | COR THERAPEUTICS INC. (US) | 2000-08-17 | — | — | WO | disclosed |
| WO-1999032454-A1 | NITROGEN CONTAINING HETEROAROMATICS WITH ORTHO-SUBSTITUTED P1'S AS FACTOR XA INHIBITORS | DU PONT PHARMACEUTICALS COMPANY (US) | 1999-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287674-A1 | Inhibitors of Factor XA and Other Serine Proteases Involved in the Coagulation Cascade | TFPI, F11, F2 | ALOX5AP 1431/4885FEN1 1168/4885 |
| US-20090221546-A1 | INHIBITORS OF FACTOR XA AND OTHER SERINE PROTEASES INVOLVED IN THE COAGULATION CASCADE | F11, F2, TFPI | ALOX5AP 1499/4885FEN1 868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.